GlassScriptPhysician profile
Alan J Schimmel
NPI 1710964671
$16,155.84
in general payments reported to CMS, 2019-2025
52 companies · $3,482 in 2025
The $3,482 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $1,578 · 2021: $2,402 · 2022: $3,279 · 2023: $2,076 · 2024: $2,312 · 2025: $3,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,696 · Honoraria: $775 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,695.57 |
| Honoraria | $775.00 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $4,518.04 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $1,299.26 | 2020-2025 | Farxiga, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $1,122.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.13 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $875.59 | 2022-2025 | Verquvo, Winrevair |
| Pfizer INC. | $786.13 | 2019-2025 | |
| Chiesi USA, INC. | $775.00 | 2025 | Juxtapid |
| Bayer Healthcare Pharmaceuticals INC. | $754.89 | 2021-2025 | |
| Amgen INC. | $521.71 | 2019-2025 | Repatha, Repatha |
| Cvrx, INC. | $374.17 | 2022-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $321.83 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $292.45 | 2019-2025 | Xact |
| Boston Scientific Corporation | $254.84 | 2020-2023 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $251.04 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $246.58 | 2025 | Amvuttra |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $245.26 | 2019-2024 | Impella |
| Shockwave Medical, INC | $219.28 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Vifor Pharma, INC. | $217.99 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $185.87 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.35 | 2019-2024 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $169.31 | 2019-2025 | Evkeeza |
| United Therapeutics Corporation | $151.04 | 2020-2024 | Tyvaso |
| Genzyme Corporation | $149.03 | 2019-2024 | |
| Siemens Medical Solutions USA, INC. | $133.71 | 2020 | |
| Integra Lifesciences Corporation | $132.26 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medtronic Vascular, INC. | $92.13 | 2020 | |
| Bridgebio Pharma, INC. | $84.92 | 2025 | Attruby |
| Novo Nordisk INC | $82.81 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Ionis Pharmaceuticals, INC. | $76.94 | 2025 | Tryngolza |
| Esperion Therapeutics, INC. | $62.45 | 2020-2024 | Nexletol |
| Innovation Technologies INC | $58.75 | 2024 | Irrisept |
| Philips North America LLC | $53.05 | 2024 | (Ck4) Mcot |
| Kiniksa Pharmaceuticals, LTD. | $51.54 | 2022-2023 | Arcalyst |
| Irhythm Technologies, INC. | $45.46 | 2022 | |
| Medtronic, INC. | $41.23 | 2024 | Linq II |
| Lexicon Pharmaceuticals, INC. | $36.50 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $35.43 | 2024 | Arcalyst |
| Kerecis Limited | $29.45 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Edwards Lifesciences Corporation | $27.65 | 2019 | |
| Inspire Medical Systems, INC. | $25.64 | 2024 | Inspire |
| Bardy Diagnostics, INC. | $24.00 | 2022 | |
| Cashflow Solutions, LLC | $23.23 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Inogen, INC. | $22.00 | 2022 | |
| Lilly USA, LLC | $21.31 | 2025 | Zepbound, Mounjaro |
| Celgene Corporation | $18.85 | 2025 | Eliquis |
| Nabriva Therapeutics, Plc | $18.48 | 2022 | |
| Baxter Healthcare | $16.81 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Reprise Biomedical, INC. | $15.63 | 2022 | |
| Daiichi Sankyo INC. | $15.29 | 2019 | |
| Smith+Nephew, INC. | $14.60 | 2021 | |
| Imperative Care, INC | $13.88 | 2024 | Symphony Catheter |
| Cardiovascular Systems INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Schimmel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.